Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBP), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. develops sublingual delivery technology designed to deliver drugs and other bioactive substances through rapid absorption under the tongue. Company news commonly covers its drug-delivery platform, applications across active pharmaceutical ingredients, therapeutics, nutraceuticals and supplements, and clinical or regulatory disclosures tied to its development activities.
Updates also include the company’s wholly owned Buzz Bomb Caffeine Company, which markets BUZZ BOMB™ caffeine in single-serving dry powder stick packs for sublingual use. Recurring corporate developments include retail distribution and sales agreements, operating and financial results, shareholder voting matters, governance updates, Nasdaq listing compliance and capital-structure actions such as reverse stock split approvals.
Aspire Biopharma (Nasdaq:ASBP) announced on March 17, 2026 that subsidiary Buzz Bomb Caffeine Company appointed John Choe as Western Sales Director. Choe is described as a 25-year industry veteran with prior roles at Yerbaé (2016–2025) and a reported 70% sales increase.
The announcement highlights Choe's experience in retail and beverage distribution, DSD and wholesale relationships, multilingual skills, and his MBA and BS degrees as assets to scale Buzz Bomb's western U.S. sales efforts.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company will feature its flagship product BUZZ BOMB™ at The Health & Fitness Show, March 16-18, 2026 in San Diego.
BUZZ BOMB™ is a 50mg single-serving dry powder stick pack designed to be sprinkled under the tongue for rapid caffeine absorption, portable dosing, and natural flavors with organic, non-GMO caffeine.
Aspire Biopharma (Nasdaq: ASBP) subsidiary Buzz Bomb Caffeine Company is launching a new BUZZ BOMB Convenience Store Pack, a six-count "Fruit Blast" offering with two each of Tropical Fruit, Mixed Berry, and Peach Mango.
Each single-serving stick contains 50mg fast-acting dry powder caffeine delivered under the tongue; rollout begins in select convenience stores starting in May.
Aspire Biopharma (Nasdaq:ASBP) announced a strategic partnership with Microsize to develop a patent-pending, rapid-delivery sublingual alprazolam powder intended to bypass the digestive tract for faster anxiety relief.
Aspire plans a Phase 1 clinical trial in mid-2026, engaged Pace for formulation and stability work, and cites >15.8 million U.S. prescriptions in 2023 and a projected global alprazolam powder market of $55.84 billion by 2032.
Aspire Biopharma (Nasdaq:ASBP) reported a major brand boost for its wholly owned Buzz Bomb Caffeine Company after sponsoring elite runner Ashley Paulson at the 2026 Jackpot Ultra Running Festival.
Key points: Buzz Bomb content surpassed 400,000 views in 48 hours, and Paulson set a new women's 100-mile world record of 12:19:34, with the company citing increased online revenue and consumer acquisition.
Aspire Biopharma (NASDAQ:ASBP) regained full compliance with Nasdaq continued listing requirements on February 20, 2026.
The company met the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1) and earlier met the $1.00 minimum bid requirement under Rule 5550(a)(2). Nasdaq confirmed the matter is closed, but Aspire will remain under a Panel Monitor through February 18, 2027.
Aspire Biopharma (NASDAQ:ASBP) announced on February 19, 2026 that its subsidiary BUZZ BOMB™ Caffeine Company named ChicExecs as its public relations agency of record as it pursues brand expansion, product innovation, and a comprehensive brand refresh.
ChicExecs will lead media relations, events, strategic partnerships, and PR campaigns to position BUZZ BOMB™—a 50mg sublingual caffeine powder in single-serving stick packs—across food, beverage, fitness, and lifestyle channels.
Aspire Biopharma (NASDAQ:ASBP) filed a provisional patent application for a proprietary sublingual powder formulation of meclizine on February 17, 2026. The formulation targets rapid-onset relief, aiming to cut typical oral onset from about 60 minutes to minutes and to support a 505(b)(2) regulatory path.
The company cites ~4.09 million U.S. prescriptions in 2023 and a $450M global meclizine market, projecting growth to $650M by 2032.
Aspire Biopharma (Nasdaq: ASBP) appointed Phillip Balatsos to its Board of Directors, effective February 6, 2026, following the planned departures of Suren Ajjarapu and Donald G. Fell.
Balatsos brings 25+ years of capital markets and entrepreneurial experience and will serve on the Audit and Compensation Committees, supporting Aspire's strategy to reformulate established drugs using its patent-pending sublingual delivery platform.
Aspire Biopharma (Nasdaq:ASBP) filed a provisional USPTO patent application on February 12, 2026 for a sublingual powder formulation of ondansetron, aimed at rapid relief of chemotherapy-, radiation- and surgery-induced nausea.
The company highlights potential near-instant absorption versus 30-minute oral tablets, plans to pursue an FDA 505(b)(2) pathway, and cites >12.5 million U.S. prescriptions and a ~$1.4B global market (2023).